Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 2/2015

01-06-2015 | Original Research

Primary Gross Tumor Volume is an Important Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Trimodality Therapy

Authors: Drexell Hunter Boggs, Andrew Hanna, Whitney Burrows, Naomi Horiba, Mohan Suntharalingam

Published in: Journal of Gastrointestinal Cancer | Issue 2/2015

Login to get access

Abstract

Purpose

This study investigated the relationship between tumor volume and outcomes in patients receiving trimodality therapy for locally advanced esophageal cancer.

Methods

Between 2001 and 2012, 67 patients treated for esophageal cancer with chemoradiotherapy followed by esophagectomy who had available gross tumor volume (GTV) information were analyzed (35 node-negative, 32 node-positive patients with primary and nodal GTV contoured as separate regions of interest). All gross tumor volumes (GTVs) were contoured at the time of radiotherapy treatment planning. GTV optimal cutoff values were determined with receiver operating characteristic analysis and deemed significant when χ 2 analysis demonstrated differences in examined prognostic variables. Overall survival (OS) and progression-free survival (PFS) were analyzed using the Cox proportional hazards model.

Results

GTVprimary (P = 0.034) and N stage were significant multivariate predictors for improved local control; GTVprimary was the only multivariate predictor of PFS (P = 0.0299) and OS (P = 0.001228) at 5 years. Univariate predictors of 5-year PFS and OS included GTVprimary, node number, and metastatic lymph node ratio. GTVprimary >85 cc was the best predictor for local failure (33.3 %; 8.7 % if ≤85 cc). GTVprimary >46 cc correlated with an increased risk of 5-year distant failure (37.1 %; 6.7 % if ≤46 cc).

Conclusions

GTVprimary was a significant multivariate predictor for improved local control, PFS, and OS. GTVprimary is a more powerful predictor of patient outcomes than traditional TNM staging and should be part of the decision-making process when determining optimal local and systemic options for patients with locally advanced esophageal cancer.
Literature
1.
go back to reference Posner MC, Minsky BD, Ilson DH. Cancer of the esophagus. In: Devita VT, Lawrence TS, Rosenberg SA, editors. Cancer principles & practice of oncology. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 887–923. Posner MC, Minsky BD, Ilson DH. Cancer of the esophagus. In: Devita VT, Lawrence TS, Rosenberg SA, editors. Cancer principles & practice of oncology. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 887–923.
10.
go back to reference Compton CC, Byrd DR, Garcia-Aguilar J, et al. editors. AJCC cancer staging atlas: a companion to the seventh editions of the AJCC cancer staging manual and handbook. 7th ed. Chicago, Illinois; 2012. p. 129–141. Compton CC, Byrd DR, Garcia-Aguilar J, et al. editors. AJCC cancer staging atlas: a companion to the seventh editions of the AJCC cancer staging manual and handbook. 7th ed. Chicago, Illinois; 2012. p. 129–141.
11.
go back to reference Eloubeidi MA, Desmond R, Arguedas MR, et al. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer. 2002;95:1434–43. doi:10.1002/cncr.10868.CrossRefPubMed Eloubeidi MA, Desmond R, Arguedas MR, et al. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer. 2002;95:1434–43. doi:10.​1002/​cncr.​10868.CrossRefPubMed
12.
go back to reference Hyun SH, Choi JY, Shim YM, et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol. 2010;17:115–22. doi:10.1245/s10434-009-0719-7.CrossRefPubMed Hyun SH, Choi JY, Shim YM, et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol. 2010;17:115–22. doi:10.​1245/​s10434-009-0719-7.CrossRefPubMed
13.
go back to reference Griffiths EA, Brummell Z, Gorthi G, et al. Tumor length as a prognostic factor in esophageal malignancy: univariate and multivariate survival analyses. J Surg Oncol. 2006;93:258–67. doi:10.1002/jso.20449.CrossRefPubMed Griffiths EA, Brummell Z, Gorthi G, et al. Tumor length as a prognostic factor in esophageal malignancy: univariate and multivariate survival analyses. J Surg Oncol. 2006;93:258–67. doi:10.​1002/​jso.​20449.CrossRefPubMed
14.
go back to reference Bradley JD, Ieumwananonthachai N, Purdy JA, et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2002;52:49–57. doi:10.1016/S0360-3016(01)01772-2.CrossRefPubMed Bradley JD, Ieumwananonthachai N, Purdy JA, et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2002;52:49–57. doi:10.​1016/​S0360-3016(01)01772-2.CrossRefPubMed
15.
go back to reference Werner-Wasik M, Swann RS, Bradley J, et al. Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93–11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;70:385–90. doi:10.1016/j.ijrobp.2007.06.034.CrossRefPubMed Werner-Wasik M, Swann RS, Bradley J, et al. Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93–11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;70:385–90. doi:10.​1016/​j.​ijrobp.​2007.​06.​034.CrossRefPubMed
16.
go back to reference Mancuso AA, Hanafee WN. Larynx and hypopharynx. In: Computed tomography and magnetic resonance imaging of the head and neck, 2nd edn. Baltimore: Williams and Wilkins; 1985. p. 241–357 Mancuso AA, Hanafee WN. Larynx and hypopharynx. In: Computed tomography and magnetic resonance imaging of the head and neck, 2nd edn. Baltimore: Williams and Wilkins; 1985. p. 241–357
18.
go back to reference Gilbert RW, Birt D, Shulman H, et al. Correlation of tumor volume with local control in laryngeal carcinoma treated by radiotherapy. Ann Otol Rhinol Laryngol. 1987;96:514–8.CrossRefPubMed Gilbert RW, Birt D, Shulman H, et al. Correlation of tumor volume with local control in laryngeal carcinoma treated by radiotherapy. Ann Otol Rhinol Laryngol. 1987;96:514–8.CrossRefPubMed
19.
go back to reference Mukherji SK, Schmalfuss IM, Castelijns J, et al. Clinical applications of tumor volume measurements for predicting outcome in patients with squamous cell carcinoma of the upper aerodigestive tract. Am J Neuroradiol. 2004;25:1425–32.PubMed Mukherji SK, Schmalfuss IM, Castelijns J, et al. Clinical applications of tumor volume measurements for predicting outcome in patients with squamous cell carcinoma of the upper aerodigestive tract. Am J Neuroradiol. 2004;25:1425–32.PubMed
20.
go back to reference Li H, Chen TW, Li ZL, et al. Tumour size of resectable oesophageal squamous cell carcinoma measured with multidetector computed tomography for predicting regional lymph node metastasis and N stage. Eur Radiol. 2012;22:2487–93. doi:10.1007/s00330-012-2512-4.CrossRefPubMed Li H, Chen TW, Li ZL, et al. Tumour size of resectable oesophageal squamous cell carcinoma measured with multidetector computed tomography for predicting regional lymph node metastasis and N stage. Eur Radiol. 2012;22:2487–93. doi:10.​1007/​s00330-012-2512-4.CrossRefPubMed
21.
go back to reference Li R, Chen TW, Hu J, et al. Tumor volume of resectable adenocarcinoma of the esophagogastric junction at multidetector CT: association with regional lymph node metastasis and N stage. Radiology. 2013;269:130–8. doi:10.1148/radiol.13122269.CrossRefPubMed Li R, Chen TW, Hu J, et al. Tumor volume of resectable adenocarcinoma of the esophagogastric junction at multidetector CT: association with regional lymph node metastasis and N stage. Radiology. 2013;269:130–8. doi:10.​1148/​radiol.​13122269.CrossRefPubMed
23.
go back to reference Boggs DH, Tarabolous C, Morris CG, et al. Analysis of pathological complete response rates with paclitaxel-based regimens in trimodality therapy for esophageal cancer. Dis Esophagus. 2014;Epublished ahead of print. doi: 10.1111/dote.12243 Boggs DH, Tarabolous C, Morris CG, et al. Analysis of pathological complete response rates with paclitaxel-based regimens in trimodality therapy for esophageal cancer. Dis Esophagus. 2014;Epublished ahead of print. doi: 10.​1111/​dote.​12243
27.
go back to reference Kim GJ, Koshy M, Hanlon AL, et al. The benefit of chemotherapy in esophageal cancer patients with residual disease after trimodality therapy. Am J Clin Oncol. 2014;Epublished ahead of print. doi: 10.1097/COC.0000000000000036 Kim GJ, Koshy M, Hanlon AL, et al. The benefit of chemotherapy in esophageal cancer patients with residual disease after trimodality therapy. Am J Clin Oncol. 2014;Epublished ahead of print. doi: 10.​1097/​COC.​0000000000000036​
28.
go back to reference He Z, Wu S, Li Q, et al. Use of the metastatic lymph node ratio to evaluate the prognosis of esophageal cancer patients with node metastasis following radical esophagectomy. PLoS One. 2013;8:e73446. doi:10.1371/journal.pone.0073446. He Z, Wu S, Li Q, et al. Use of the metastatic lymph node ratio to evaluate the prognosis of esophageal cancer patients with node metastasis following radical esophagectomy. PLoS One. 2013;8:e73446. doi:10.​1371/​journal.​pone.​0073446.
Metadata
Title
Primary Gross Tumor Volume is an Important Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Trimodality Therapy
Authors
Drexell Hunter Boggs
Andrew Hanna
Whitney Burrows
Naomi Horiba
Mohan Suntharalingam
Publication date
01-06-2015
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 2/2015
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-015-9699-y

Other articles of this Issue 2/2015

Journal of Gastrointestinal Cancer 2/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.